LIFECORE BIOMEDICAL, INC. Other Revenue, Net (Deprecated 2018-01-31)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Other Revenue, Net (Deprecated 2018-01-31) of $37.91 million for the 3-month period ending 2018-02-25, per its 10-Q filed 2018-04-05.
Discontinued › Income Statement › Other Income
us-gaap:OtherSalesRevenueNet · last filed 2018-04-05
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2018-02-25 was $37.91M, a 3.06% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-11-26 was $34.42M, a 25.11% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-08-27 was $29.25M, a 39.35% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for the quarter ending 2017-05-28 was $28.05M, a 32.99% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2017 was $161.34M, a 3.63% decline from fiscal 2016.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2016 was $167.42M, a 2.42% increase from fiscal 2015.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2015 was $163.46M, a 19.10% increase from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. other revenue, net (deprecated 2018-01-31) for fiscal 2014 was $137.25M, a 3.37% increase from fiscal 2013.
| Period end | Other Revenue, Net (Deprecated 2018-01-31) 3 month | Other Revenue, Net (Deprecated 2018-01-31) 6 month | Other Revenue, Net (Deprecated 2018-01-31) 9 month | Other Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-02-25 | $37.91M 10-Q · filed 2018-04-05 | $72.32M derived: sum of 2 quarters · filed 2018-04-05 | $101.57M 10-Q · filed 2018-04-05 | $129.62M derived: sum of 4 quarters · filed 2018-04-05 |
| 2017-11-26 | $34.42M 10-Q · filed 2018-01-05 | $63.66M 10-Q · filed 2018-01-05 | $91.72M derived: sum of 3 quarters · filed 2018-03-15 | $130.82M derived: sum of 4 quarters · filed 2018-04-05 |
| 2017-08-27 | $29.25M 10-Q · filed 2017-09-28 | $57.30M derived: sum of 2 quarters · filed 2018-03-15 | $96.40M derived: sum of 3 quarters · filed 2018-04-05 | $142.36M derived: sum of 4 quarters · filed 2018-04-05 |
| 2017-05-28 | $28.05M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $67.15M derived: sum of 2 quarters · filed 2018-04-05 | $113.11M derived: sum of 3 quarters · filed 2018-04-05 | $161.34M 10-K/A · filed 2018-03-15 |
| 2017-02-26 | $39.10M 10-Q · filed 2018-04-05 | $85.06M derived: sum of 2 quarters · filed 2018-04-05 | $133.28M 10-Q · filed 2018-04-05 | $175.14M derived: sum of 4 quarters · filed 2018-04-05 |
| 2016-11-27 | $45.95M 10-Q · filed 2018-01-05 | $94.18M 10-Q · filed 2018-01-05 | $136.04M derived: sum of 3 quarters · filed 2018-03-15 | $171.35M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-08-28 | $48.23M 10-Q · filed 2017-09-28 | $90.08M derived: sum of 2 quarters · filed 2018-03-15 | $125.39M derived: sum of 3 quarters · filed 2018-03-15 | $169.37M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-05-29 | $41.86M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $77.17M derived: sum of 2 quarters · filed 2018-03-15 | $121.14M derived: sum of 3 quarters · filed 2018-03-15 | $167.42M 10-K/A · filed 2018-03-15 |
| 2016-02-28 | $35.31M 10-Q · filed 2017-04-07 | $79.28M derived: sum of 2 quarters · filed 2017-04-07 | $125.56M 10-Q · filed 2017-04-07 | $163.14M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-11-29 | $43.97M 10-Q · filed 2017-01-05 | $90.25M 10-Q · filed 2017-01-05 | $127.83M derived: sum of 3 quarters · filed 2018-03-15 | $165.74M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-08-30 | $46.28M 10-Q · filed 2016-09-29 | $83.86M derived: sum of 2 quarters · filed 2018-03-15 | $121.76M derived: sum of 3 quarters · filed 2018-03-15 | $163.36M derived: sum of 4 quarters · filed 2018-03-15 |
| 2015-05-31 | $37.59M derived: 10-K/A 12 month − 10-Q 9 month · filed 2018-03-15 | $75.49M derived: sum of 2 quarters · filed 2018-03-15 | $117.09M derived: sum of 3 quarters · filed 2018-03-15 | $163.46M 10-K/A · filed 2018-03-15 |
| 2015-03-01 | $37.90M 10-Q · filed 2016-03-30 | $79.50M derived: sum of 2 quarters · filed 2016-03-30 | $125.88M 10-Q · filed 2016-03-30 | $157.92M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-11-30 | $41.60M 10-Q · filed 2016-01-07 | $87.97M 10-Q · filed 2016-01-07 | $120.02M derived: sum of 3 quarters · filed 2016-08-01 | $153.32M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-08-31 | $46.37M 10-Q · filed 2015-10-01 | $78.42M derived: sum of 2 quarters · filed 2016-08-01 | $111.72M derived: sum of 3 quarters · filed 2016-08-01 | $148.37M derived: sum of 4 quarters · filed 2016-08-01 |
| 2014-05-25 | $32.05M derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-01 | $65.35M derived: sum of 2 quarters · filed 2016-08-01 | $102.00M derived: sum of 3 quarters · filed 2016-08-01 | $137.25M 10-K · filed 2016-08-01 |
| 2014-02-23 | $33.30M 10-Q · filed 2015-04-02 | $69.95M derived: sum of 2 quarters · filed 2015-04-02 | $105.20M 10-Q · filed 2015-04-02 | $129.14M derived: sum of 4 quarters · filed 2015-07-31 |
| 2013-11-24 | $36.65M 10-Q · filed 2015-01-09 | $71.89M 10-Q · filed 2015-01-09 | $95.84M derived: sum of 3 quarters · filed 2015-07-31 | $130.09M derived: sum of 4 quarters · filed 2015-07-31 |
| 2013-08-25 | $35.24M 10-Q · filed 2014-10-08 | $59.19M derived: sum of 2 quarters · filed 2015-07-31 | $93.44M derived: sum of 3 quarters · filed 2015-07-31 | |
| 2013-05-26 | $23.94M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | $58.19M derived: sum of 2 quarters · filed 2015-07-31 | $132.77M 10-K · filed 2015-07-31 | |
| 2013-02-24 | $34.25M 10-Q · filed 2014-03-28 | $108.83M 10-Q · filed 2014-03-28 | ||
| 2012-05-27 | $114.49M 10-K · filed 2014-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |